ONODERA GT Pharma Overview

  • Year Founded
  • 2014

Year Founded

  • Status
  • Private

  • Employees
  • 47

Employees

  • Latest Deal Type
  • Series A

  • Investors
  • 7

ONODERA GT Pharma General Information

Description

Developer of gene therapy intended to carry out research and development on neurodegenerative diseases. The company's drugs specialize in developing gene therapies for refractory diseases primarily focusing on Parkinson's disease, amyotrophic lateral sclerosis (ALS), and Alzheimer's disease, enabling patients to get therapies while suffering from refractory illnesses.

Contact Information

Formerly Known As
Gene Therapy Research Institution
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 25-22, Tonomachi 3-chome, Kawasaki-ku
  • Kawasaki-shi
  • Kanagawa, 210-0821
  • Japan
+81
Primary Industry
Biotechnology
Vertical(s)
Corporate Office
  • 25-22, Tonomachi 3-chome, Kawasaki-ku
  • Kawasaki-shi
  • Kanagawa, 210-0821
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

ONODERA GT Pharma Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series A) 31-Oct-2022 Completed Clinical Trials - Phase 2
4. Later Stage VC 24-Jun-2020 Completed Pre-Clinical Trials
3. Later Stage VC (Series A) 24-Dec-2019 Completed Pre-Clinical Trials
2. Secondary Transaction - Private 19-Feb-2016 $163K Cancelled Pre-Clinical Trials
1. Corporate Completed Pre-Clinical Trials
To view ONODERA GT Pharma’s complete valuation and funding history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

ONODERA GT Pharma Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of gene therapy intended to carry out research and development on neurodegenerative diseases. The company's dr
Biotechnology
Kanagawa, Japan
47 As of 2023

Rockville, MD
 

Amsterdam, Netherlands
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

ONODERA GT Pharma Competitors (5)

One of ONODERA GT Pharma’s 5 competitors is Regenxbio, a Formerly VC-backed company based in Rockville, MD.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Regenxbio Formerly VC-backed Rockville, MD
uniQure Formerly VC-backed Amsterdam, Netherlands
Sarepta Therapeutics Formerly VC-backed Cambridge, MA
Rocket Pharmaceuticals Formerly VC-backed Cranbury, NJ
BioMarin Pharmaceutical Formerly PE-Backed San Rafael, CA
You’re viewing 5 of 5 competitors. Get the full list »

ONODERA GT Pharma Patents

ONODERA GT Pharma Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
EP-4328313-A1 Adeno-associated virus virion for treating ornithine transcarbamylase deficiency Pending 21-Apr-2021
EP-4328313-A4 Adeno-associated virus virion for treating ornithine transcarbamylase deficiency Pending 21-Apr-2021
US-20250339480-A1 Adeno-associated virus virion for treating ornithine transcarbamylase deficiency Pending 21-Apr-2021
WO-2022224372-A1 Adeno-associated virus virion for treating ornithine transcarbamylase deficiency Inactive 21-Apr-2021
JP-2021097617-A Adeno-associated virus virion for treatment of ornithine transcarbamylase deficiency Pending 20-Dec-2019
To view ONODERA GT Pharma’s complete patent history, request access »

ONODERA GT Pharma Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

ONODERA GT Pharma Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Healthcare Innovation Venture Capital Minority
PTC Therapeutics Corporation Minority
Sekisui Chemical Corporation Minority
Alfresa Holdings Corporation Minority
Environment Friendly Holdings Holding Company Minority
You’re viewing 5 of 7 investors. Get the full list »

ONODERA GT Pharma Investments (1)

ONODERA GT Pharma’s most recent deal was a Joint Venture with Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution). The deal was made on 02-Aug-2017.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Adeno-Associated Virus Gene Therapies (Agilis Biotherapeutics & Gene Therapy Research Institution) 02-Aug-2017 Joint Venture Drug Discovery
To view ONODERA GT Pharma’s complete investments history, request access »

ONODERA GT Pharma FAQs

  • When was ONODERA GT Pharma founded?

    ONODERA GT Pharma was founded in 2014.

  • Where is ONODERA GT Pharma headquartered?

    ONODERA GT Pharma is headquartered in Kanagawa, Japan.

  • What is the size of ONODERA GT Pharma?

    ONODERA GT Pharma has 47 total employees.

  • What industry is ONODERA GT Pharma in?

    ONODERA GT Pharma’s primary industry is Biotechnology.

  • Is ONODERA GT Pharma a private or public company?

    ONODERA GT Pharma is a Private company.

  • What is the current valuation of ONODERA GT Pharma?

    The current valuation of ONODERA GT Pharma is .

  • What is ONODERA GT Pharma’s current revenue?

    The current revenue for ONODERA GT Pharma is .

  • Who are ONODERA GT Pharma’s investors?

    Healthcare Innovation, PTC Therapeutics, Sekisui Chemical, Alfresa Holdings, and Environment Friendly Holdings are 5 of 7 investors who have invested in ONODERA GT Pharma.

  • Who are ONODERA GT Pharma’s competitors?

    Regenxbio, uniQure, Sarepta Therapeutics, Rocket Pharmaceuticals, and BioMarin Pharmaceutical are competitors of ONODERA GT Pharma.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process